Allergan (AGN) Declares $0.74 Quarterly Dividend; 2.1% Yield

FDA comments on new efforts to protect women’s health and help to ensure the safety of breast implants

There has been a growing discussion in recent months around the safety of certain breast implants, with regulatory agencies around the world weighing the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Its an issue that has been a priority for us at the U.S. Food and Drug Administration since 2011 when we warned women that the available information at the time indicated that there is a risk for women with breast implants, especially those with textured implants, for developing this disease.

Since that time, we have worked diligently to fill the gaps in knowledge, such as... More

Allergan (AGN) shareholder Appaloosa continues to believe separating roles of Chairman and CEO is necessary

Appaloosa LP today issued a statement following Allergan plcs (NYSE: AGN) (Allergan) Annual General Meeting of Shareholders on May 1, 2019 regarding Allergan shareholders vote on Appaloosas proposal to separate the Chairman and CEO roles.

Allergan shareholders are clearly dissatisfied with managements performance,... More

Allergan (AGN) Announces Results from 2019 Annual General Meeting of Shareholders

Allergan plc (NYSE: AGN) today announced the voting results, representing 85.9 percent of shares eligible to be voted, from its Annual General Meeting of Shareholders held on May 1, 2019 in Dublin, Ireland. Shareholders elected all of the 11 nominees as members of the Board of Directors, approved an advisory resolution on executive compensation, ratified the appointment of Allergan's independent auditor for fiscal year 2019, approved proposals related to the authority of the Directors to issue shares under certain specified conditions, and rejected a shareholder proposal calling for an immediate separation of... More